

Market Applicability														
Market	DC	FL & FHK	FL MMA	FL LTC	GA	KS	KY	MD	NJ	NV	NY	TN	TX	WA
Applicable	X	X	NA	NA	X	NA	X	X	X	X	X	NA	NA	X

*FHK- Florida Healthy Kids

Temodar (temozolomide)

Override(s)	Approval Duration
Prior Authorization Quantity Limit	1 year

Medications	Line of Business Criteria Applies	Quantity Limit
Temodar (temozolomide) capsules	Commercial, HIX, All MCD	May be subject to quantity limit
Temodar (temozolomide) vial	Commercial, HIX, CCC, AGP, VA MCD	N/A

APPROVAL CRITERIA

Requests for Temodar (temozolomide) may be approved if the following criteria are met:

- I. Individual has a diagnosis of one of the following:
 - A. Bone Cancer – for Ewing Sarcoma (NCCN 2A); **OR**
 - B. Central Nervous System (CNS) Cancers -
 1. Newly diagnosed for glioblastoma multiforme and using in adjunct therapy WITH radiotherapy or maintenance therapy AFTER radiotherapy; **OR**
 2. Refractory anaplastic astrocytoma and disease has progressed post-chemotherapy with a nitrosourea and procarbazine; **OR**
 3. Recurrent or progressive low-grade infiltrative supratentorial astrocytoma/oligodendroglioma, (label, NCCN 2A); **OR**
 4. Anaplastic gliomas (NCCN 2A); **OR**
 5. Glioblastomas (NCCN 2A); **OR**
 6. Adult intracranial and spinal ependymoma (excluding subependymoma) (NCCN 2A); **OR**
 7. Adult medulloblastoma for those with prior chemotherapy (NCCN 2A); **OR**
 8. Primary CNS Lymphoma with induction therapy (NCCN 2A); **OR**

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.

Market Applicability														
Market	DC	FL & FHK	FL MMA	FL LTC	GA	KS	KY	MD	NJ	NV	NY	TN	TX	WA
Applicable	X	X	NA	NA	X	NA	X	X	X	X	X	NA	NA	X

*FHK- Florida Healthy Kids

- 9. Primary CNS Lymphoma in relapsed or refractory disease (NCCN 2A); **OR**
- 10. Recurrent brain metastases in those with stable systemic disease or reasonable systemic treatment options if active against the primary tumor (NCCN 2A);

- C. Lung Neuroendocrine Tumors(NCCN 2A); **OR**

- D. Melanoma -
 - 1. As monotherapy for metastatic or unresectable disease (NCCN 2A); **OR**
 - 2. As monotherapy for disease progression (NCCN 2A);

- E. Neuroendocrine Tumors of the Pancreas (NCCN 2A); **OR**

- F. Neuroendocrine Tumors of the Gastrointestinal Tract, Lung and Thymus (Carcinoid Tumors) (NCCN 2A); **OR**

- G. Neuroendocrine and Adrenal Tumors -
 - 1. As monotherapy for Pheochromocytoma/Paraganglioma with distant metastases (NCCN 2A); **OR**

- H. Mycosis Fungoides/Sézary Syndrome (NCCN 2A); **OR**

- I. Small Cell Lung Cancer (NCCN 2A). **OR**

- J. Soft Tissue Sarcoma
 - 1. In palliative chemotherapy (NCCN 2A); **OR**
 - 2. Nonpleomorphic rhabdomyosarcoma in combination with vincristine and irinotecan (NCCN 2A); **OR**
 - 3. Solitary fibrous tumor and hemangiopericytoma in combination with bevacizumab (NCCN 2A); **OR**

- K. Uterine Neoplasms (NCCN 2A); **OR**

- L. Uveal Melanoma, for metastatic or unresectable disease (NCCN 2A).

State Specific Mandates		
State name	Date effective	Mandate details (including specific bill if applicable)
N/A		N/A

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.

Market Applicability														
Market	DC	FL & FHK	FL MMA	FL LTC	GA	KS	KY	MD	NJ	NV	NY	TN	TX	WA
Applicable	X	X	NA	NA	X	NA	X	X	X	X	X	NA	NA	X

*FHK- Florida Healthy Kids

	N/A	
--	-----	--

Key References:

Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.: 2018. URL: <http://www.clinicalpharmacology.com>. Updated periodically.

DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. <http://dailymed.nlm.nih.gov/dailymed/about.cfm>. Accessed: 4/2018.

DrugPoints® System [Internet Database]. Greenwood Village, CO: Thomson Reuters (Healthcare) Inc. Updated periodically.

Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2018; Updated periodically.

The NCCN Drugs & Biologics Compendium (NCCN Compendium™) © 2018 National Comprehensive Cancer Network, Inc. Available at: NCCN.org. Updated periodically.

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.
 CRX-ALL-0199-18